# US 2018/0022827 A1 · Antibodies to risperidone haptens and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022827 A1
- Document ID: US20180022827A1
- Status: Published application
- Kind: A1
- Application number: 15/694,609
- Filed: 2017-09-01
- Published: 2018-01-25
- Earliest claimed: 2012-08-21
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica NV
- Inventors: Eric Hryhorenko; Banumathi Sankaran; Thomas R. DeCory; Theresa Tubbs; Linda Colt; Maarten Vliegen; Pieter Rik Haspeslagh
- Web page: https://patentgrep.com/patent/US20180022827A1

## CPC

- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- G01N 2800/302: Schizophrenia
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

## Claims

### Claim 1

A method of detecting risperidone in a sample, the method comprising:
(i) generating an antibody or a binding fragment thereof that specifically binds to risperidone in response to a conjugate of a compound of Formula I and an immunogenic carrier,
Formula I:
wherein:
R1 is H, or OH;
R2 is
or O(CH2)rNHC(O)(CH2)mCO2H;
wherein:
r is 1, 2, 3, 4, or 5;
m is 1, 2, 3, 4, or 5; and
n is 1, 2, 3, 4, or 5;
(ii) contacting a sample with the antibody or binding fragment thereof labeled with a detectable marker, wherein the labeled antibody or binding fragment and risperidone present in the sample form a labeled complex; and
(iii) detecting the labeled complex thereby detecting risperidone in the sample.

### Claim 2

A competitive immunoassay method for detecting risperidone in a sample, the method comprising:
(i) generating an antibody or a binding fragment thereof that specifically binds to risperidone in response to a conjugate of a compound of Formula I and an immunogenic carrier,
Formula I:
wherein:
R1 is H, or OH;
R2 is
or O(CH2)rNHC(O)(CH2)mCO2H;
wherein:
r is 1, 2, 3, 4, or 5;
m is 1, 2, 3, 4, or 5; and
n is 1, 2, 3, 4, or 5;
(ii) contacting a sample with the antibody or binding fragment thereof, and with risperidone or a competitive binding partner of risperidone, wherein one of the antibody or binding fragment thereof and the risperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample risperidone competes with the risperidone or competitive binding partner thereof for binding to the antibody or binding fragment thereof; and
(ii) detecting the label thereby detecting sample risperidone.

### Claim 3 (depends on 2)

The method of claim 2, wherein the risperidone or competitive binding partner thereof is labeled with the detectable marker.

### Claim 4 (depends on 2)

The method of claim 2, wherein the antibody or binding fragment thereof is labeled with the detectable marker.

### Claim 5 (depends on 2)

The method of claim 2, wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.

### Claim 6 (depends on 1)

The method of claim 1, further comprising detecting the presence of one or more analytes in addition to risperidone.

### Claim 7 (depends on 6)

The method of claim 6, wherein the one or more analytes are anti-psychotic drugs other than risperidone.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-psychotic drugs other than risperidone are selected from the group consisting of: paliperidone, aripiprazole, quetiapine, olanzapine, and metabolites thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the detection of risperidone is an indication of patient adherence with prescribed risperidone therapy.

### Claim 10 (depends on 1)

The method of claim 1, wherein the detection of risperidone is used to determine whether a patient should be converted from an oral risperidone regimen to an injectable anti-psychotic regimen.

### Claim 11 (depends on 1)

The method of claim 1, wherein the detection of risperidone is used to determine if the dose level or dosing interval of oral or injectable risperidone should be increased or decreased to ensure attainment or maintenance of efficacious or safe drug levels.

### Claim 12 (depends on 1)

The method of claim 1, wherein the detection of risperidone is an aid in the initiation of risperidone therapy by providing evidence of the attainment of minimum pK levels.

### Claim 13 (depends on 1)

The method of claim 1, wherein the detection of risperidone is used to determine bioequivalence of risperidone in multiple formulations or from multiple sources.

### Claim 14 (depends on 1)

The method of claim 1, wherein the detection of risperidone is used to assess the impact of polypharmacy and potential drug-drug interactions.

### Claim 15 (depends on 1)

The method of claim 1, wherein the detection of risperidone is an indication that a patient should be excluded from or included into a clinical trial and is an aid in the subsequent monitoring of adherence to clinical trial medication requirements.

### Claim 16 (depends on 2)

The method of claim 2, further comprising detecting the presence of one or more analytes in addition to risperidone.

### Claim 17 (depends on 16)

The method of claim 16, wherein the one or more analytes are anti-psychotic drugs other than risperidone.

### Claim 18 (depends on 17)

The method of claim 17, wherein the anti-psychotic drugs other than risperidone are selected from the group consisting of: paliperidone, aripiprazole, quetiapine, olanzapine, and metabolites thereof.

### Claim 19 (depends on 2)

The method of claim 2, wherein the detection of risperidone is an indication of patient adherence with prescribed risperidone therapy.

### Claim 20 (depends on 2)

The method of claim 2, wherein the detection of risperidone is used to determine whether a patient should be converted from an oral risperidone regimen to an injectable anti-psychotic regimen.

### Claim 21 (depends on 2)

The method of claim 2, wherein the detection of risperidone is used to determine if the dose level or dosing interval of oral or injectable risperidone should be increased or decreased to ensure attainment or maintenance of efficacious or safe drug levels.

### Claim 22 (depends on 2)

The method of claim 2, wherein the detection of risperidone is an aid in the initiation of paliperidone therapy by providing evidence of the attainment of minimum pK levels.

### Claim 23 (depends on 2)

The method of claim 2, wherein the detection of risperidone is used to determine bioequivalence of risperidone in multiple formulations or from multiple sources.

### Claim 24 (depends on 2)

The method of claim 2, wherein the detection of risperidone is used to assess the impact of polypharmacy and potential drug-drug interactions.

### Claim 25 (depends on 2)

The method of claim 2, wherein the detection of risperidone is an indication that a patient should be excluded from or included into a clinical trial and is an aid in the subsequent monitoring of adherence to clinical trial medication requirements.
